The Evolving Role of In Vitro-In Vivo Correlation in Model-Informed Drug Development: A Multi-Stakeholder Perspective. [PDF]
CPT Pharmacometrics Syst PharmacolChenel M +7 more
europepmc +1 more source
Validating Physiologically-Based Pharmacokinetic Models Using the Continuous Ranked Probability Score: Beyond Being Correct on Average. [PDF]
CPT Pharmacometrics Syst PharmacolSluijterman L +3 more
europepmc +1 more source
Albumin Levels Are Predictive of Cachexia-Induced Time-Dependent Clearance of Therapeutic Antibodies: A Physiologically Based Pharmacokinetic Model of Durvalumab. [PDF]
CPT Pharmacometrics Syst PharmacolProctor JR, Wong H.
europepmc +1 more source
The Basel Modeling and Simulation Seminar: 20 Editions of Fostering Local Exchange in Pharmacometrics. [PDF]
CPT Pharmacometrics Syst Pharmacolvan Donge T +6 more
europepmc +1 more source
Enhance Multistate Models With Clinically Meaningful Graphs. [PDF]
CPT Pharmacometrics Syst PharmacolGrevel J.
europepmc +1 more source
Medicament inspection and pharmacometrics.
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 1998 openaire +2 more sources
Retrieval Augmented Generation (RAG) for Evaluating Regulatory Compliance of Drug Information and Clinical Trial Protocols. [PDF]
CPT Pharmacometrics Syst PharmacolWaikar S, Bhat AG, Ramanathan M.
europepmc +1 more source
Response to "Enhance Multistate Models With Clinically Meaningful Graphs". [PDF]
CPT Pharmacometrics Syst PharmacolIbrahim MMA, Kjellsson MC, Karlsson MO.
europepmc +1 more source
Population Physiologically-Based Pharmacokinetic Modeling to Determine Ontogeny: A Quantitative Clinical Pharmacology Example in Pediatric Rare Disease. [PDF]
CPT Pharmacometrics Syst PharmacolCleary Y +4 more
europepmc +1 more source
The Advance of In Silico Evidence to Transform Pediatric Drug Development for Rare Diseases. [PDF]
CPT Pharmacometrics Syst PharmacolKnöchel J +5 more
europepmc +1 more source